Toceranib therapy for hepatic fibrosarcoma in a dog
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
A 12-year-old neutered male Maltese was brought to our hospital with loss of appetite, generalized alopecia, anemia, and a palpable abdominal mass. Ultrasonography revealed multiple abdominal masses in the liver and spleen. Subsequently, splenectomy and liver biopsy were performed, and the masses were histologically diagnosed as metastatic fibrosarcomas of unknown primary origin. The owner refused further investigations such as computed tomography and hepatectomy, therefore, we decided to initiate chemotherapy in the form of metronomic therapy with toceranib phosphate, which has several advantages, such as better tolerability, low cost, and convenience. The size and number of hepatic fibrosarcomas continued to increase despite continued administration of toceranib (10 mg/dog, PO, q48h). The dog died approximately 43 days after initiation of the toceranib treatment. To the best of our knowledge, this is the first report on toceranib therapy for metastatic hepatic fibrosarcoma in a dog.
Abstract
A 12-year-old neutered male Maltese was brought to our hospital with loss of appetite, generalized alopecia, anemia, and a palpable abdominal mass. Ultrasonography revealed multiple abdominal masses in the liver and spleen. Subsequently, splenectomy and liver biopsy were performed, and the masses were histologically diagnosed as metastatic fibrosarcomas of unknown primary origin. The owner refused further investigations such as computed tomography and hepatectomy, therefore, we decided to initiate chemotherapy in the form of metronomic therapy with toceranib phosphate, which has several advantages, such as better tolerability, low cost, and convenience. The size and number of hepatic fibrosarcomas continued to increase despite continued administration of toceranib (10 mg/dog, PO, q48h). The dog died approximately 43 days after initiation of the toceranib treatment. To the best of our knowledge, this is the first report on toceranib therapy for metastatic hepatic fibrosarcoma in a dog.
참고문헌 (16)
- Calvalido J, "Comparison of serum cytokine levels between dogs with multicentric lymphoma and healthy dogs", Vet Immunol Immunopathol, 182, pp.106~114 (2016)
- Carmeliet P, "VEGF as a key mediator of angiogenesis in cancer", Oncology, 69, pp.4~10 (2005)
- Day MJ, "A review of pathological diagnoses made from 87 canine splenic biopsies", J Small Anim Pract, 36, pp.426~433 (1995)
- Frezoulis P, "The role of toceranib phosphate in dogs with non-mast cell neoplasia : A systematic review", Vet Comp Oncol, 20, pp.362~371 (2022)
- Gardner HL, "Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma", Vet Res, 11, pp.131~ (2015)
- Goldschmidt MH, "Tumors in domestic animals", pp.45~117 (2002), Iowa State University Press
- Hisada Y, "Tissue factor and cancer : regulation, tumor growth, and metastasis", Semin Thromb Hemost, 45, pp.385~395 (2019)
- Jang JK, "Phase 1 dose-escalation study with LEC", chTNT-3 and toceranib phosphate(Palladia®)in dogs with spontaneous malignancies, 2015, pp.7, 167~174
- 김경태, "성인의 미분화간육종 치료 체험 1예", Clinical and Molecular Hepatology, 13(1), pp.96~102 (2007), 대한간학회
- Laver T, "Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma", Vet Comp Oncol, 16, pp.E23~E29 (2018)
- Milovancev M, "Antiproliferative effects of masitinib and imatinib against canine oral fibrosarcoma in vitro", Vet Res, 12, pp.85~ (2016)
- Mitchell L, "Clinical and immunomodulatory effects of Toceranib combined with low-dose cyclophosphamide in dogs with cancer", J Vet Intern Med, 26, pp.355~362 (2012)
- Nguyen SM, "Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document", Vet Comp Oncol, 13, pp.176~183 (2015)
- Pan X, "Safety evaluation of combination CCNU and continuous toceranib phosphate(Palladia®)in tumour-bearing dogs : a phase Ⅰ dose-finding study", Vet Comp Oncol, 14, pp.202~209 (2016)
- Patnaik AK, "Canine hepatic neoplasms : a clinicopathologic study", Vet pathol, 17, pp.553~564 (1980)
- Spangler WL, "Primary mesenchymal(nonangiomatous", nonlymphomatous)neoplasms occurring in the canine spleen : anatomic classification, immunohistochemistry, and mitotic activity correlated with patient survival, 1994, pp.31, 37~47